|
US2009017069A1
|
|
SARS Vaccine Compositions and Methods of Making and Using Them
|
|
US2008227686A1
|
|
Novel Peptides that Promote Lipid Efflux
|
|
WO2008094905A2
|
|
Encapsulated hdl mimetic peptides
|
|
US2008206142A1
|
|
Novel Peptides That Promote Lipid Efflux
|
|
US2008138284A1
|
|
Novel Peptides That Promote Lipid Efflux
|
|
WO2007149355A2
|
|
Novel peptides that promote lipid efflux
|
|
US2007138094A1
|
|
Systems and methods using a solvent for the removal of lipids from fluids
|
|
US2007026006A1
|
|
Method of treating cancer cells to create a modified cancer cell that provokes an immunogenic response
|
|
AU2006200008A1
|
|
A method of treating infectious diseases
|
|
US2006172939A1
|
|
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
US6991727B2
|
|
Hollow fiber contactor systems for removal of lipids from fluids
|
|
CA2529965A1
|
|
Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
|
|
AU2004264842A1
|
|
Modified viral particles with immunogenic properties and reduced lipid content useful for treating and preventing infectious diseases
|
|
US7407662B2
|
|
Modified viral particles with immunogenic properties and reduced lipid content
|
|
AU2004260632A1
|
|
Methods and apparatus for creating particle derivatives of HDL with reduced lipid content
|
|
WO2004017946A1
|
|
Treating alzheimers using delipidated protein particles
|
|
US7407663B2
|
|
Modified immunodeficiency virus particles
|
|
EP1412045A1
|
|
Systems and methods using a solvent for the removal of lipids from fluids
|
|
AU2002322284A1
|
|
Systems and methods using multiple solvents for the removal of lipids from fluids
|
|
EP1409108A1
|
|
Hollow fiber contactor systems for removal of lipids from fluids
|
